Physician profile
Acadia M Joines
NPI 1578913323
$1,311.85
in general payments reported to CMS, 2019-2025
15 companies · $663 in 2025
The $663 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $183 · 2023: $312 · 2024: $153 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $137.03 | 2025 | Affinity, Puraply Wound Matrix, Apligraf |
| Gilead Sciences, INC. | $125.00 | 2025 | Livdelzi |
| La Jolla Pharmaceutical Company | $124.99 | 2025 | Zevtera |
| Ferring Pharmaceuticals INC. | $116.25 | 2023 | Rebyota |
| Kerecis Limited | $110.75 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Biohaven Pharmaceutical Holding Company LTD. | $107.17 | 2022 | |
| Corcept Therapeutics | $100.00 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $82.84 | 2024 | Auvelity |
| Janssen Pharmaceuticals, INC | $82.80 | 2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.26 | 2023 | Jardiance |
| Glaxosmithkline, LLC. | $76.05 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $75.70 | 2023-2025 | Airsupra |
| Smith+Nephew, INC. | $39.61 | 2024 | Pico 7, Collagenase Santyl |
| Bayer Healthcare Pharmaceuticals INC. | $30.99 | 2024 | |
| Integra Lifesciences Corporation | $21.41 | 2025 | Tcc-Ez |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Acadia Joines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.